Biotech firm Hangzhou Diagens Biotechnology is banking on AI-powered chromosome testing to drive profit growth following its Hong Kong listing, as China’s falling fertility rate spurs demand for assisted reproduction.
“In China, many young people do not want to marry or have children, and by the time they decide to start a family, they need medical help to do so,” Diagens’ founder and executive director, Song Ning, said.
“We are meeting an increasing number of couples every year who struggle to…
Chinese company to use AI-powered chromosome testing to boost profits and fast-track IVF
